Vol 58, No 1 (2024)
Short Communication
Published online: 2023-06-28

open access

Page views 590
Article views/downloads 439
Get Citation

Connect on Social Media

Connect on Social Media

KinesioTaping: impact on non-motor symptoms in cervical dystonia patients treated with botulinum toxin injection

Małgorzata Dec-Ćwiek1, Katarzyna Sawczyńska1, Karolina Porębska1, Marcin Kubala2, Magdalena Witkowska1, Kinga Żmijewska23
Pubmed: 37376975
Neurol Neurochir Pol 2024;58(1):127-133.

Abstract

Aim of the study. To assess whether combined therapy with botulinum toxin injections (BoNT) and KinesioTaping could be helpful in managing non-motor symptoms (NMS) of cervical dystonia (CD).

Material and methods. Seventeen patients with CD were enrolled in this single-centre, prospective, evaluator-blinded, randomised, crossover trial. We compared three forms of treatment: BoNT treatment alone, or combined with KinesioTaping, or combined with ShamTaping. NMS were assessed using the 14-item self-reported questionnaire proposed by Klingelhoefer, the Hospital Anxiety and Depression Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI).

Results. There were no significant differences between the groups concerning mean results of HADS and PSQI scales, or mean total number of NMS after the procedures. The mean change from baseline HADS and PSQI scores, and total number of NMS after the procedure, also did not differ significantly between groups. ShamTaping combined with BoNT significantly increased the prevalence of pain.

Conclusions and clinical implications. Our study did not confirm the effectiveness of combined therapy of BoNT and KinesioTaping in the management of NMS in patients with CD. Due to a potential negative effect of improper taping on pain in CD, patients with CD should only experience KinesioTaping as an adjunctive therapy, and if it is performed by a trained, experienced physiotherapist.

Article available in PDF format

View PDF Download PDF file

References

  1. Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. 2015; 262(10): 2201–2213.
  2. Klingelhoefer L, Martino D, Martinez-Martin P, et al. Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. Basal Ganglia. 2014; 4(3-4): 117–120.
  3. Bergenheim AT, Nordh E, Larsson E, et al. Selective peripheral denervation for cervical dystonia: long-term follow-up. J Neurol Neurosurg Psychiatry. 2015; 86(12): 1307–1313.
  4. Han V, Skorvanek M, Smit M, et al. Prevalence of non-motor symptoms and their association with quality of life in cervical dystonia. Acta Neurol Scand. 2020; 142(6): 613–622.
  5. Stamelou M, Edwards MJ, Hallett M, et al. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2012; 135(Pt 6): 1668–1681.
  6. Sławek J, Jost WH. Botulinum neurotoxin in cervical dystonia revisited - recent advances and unanswered questions. Neurol Neurochir Pol. 2021; 55(2): 125–132.
  7. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011; 18(1): 5–18.
  8. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19): 1818–1826.
  9. Francisco GE, Balbert A, Bavikatte G, et al. A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus. J Rehabil Med. 2021; 53(1): jrm00134.
  10. Eichenseer SR, Stebbins GT, Comella CL. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014; 20(4): 405–408.
  11. Comella CL, Jankovic J, Truong DD, et al. U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011; 308(1-2): 103–109.
  12. Kase K, Wallis J, Kase T. Clinical therapeutic application of the KinesioTaping Methods. Japan: Ikai Co Ltd 2013.
  13. Pelosin E, Avanzino L, Marchese R, et al. Kinesiotaping reduces pain and modulates sensory function in patients with focal dystonia: a randomized crossover pilot study. Neurorehabil Neural Repair. 2013; 27(8): 722–731.
  14. Dec-Ćwiek M, Porębska K, Sawczyńska K, et al. KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients. Brain Behav. 2022; 12(4): e2541.
  15. Jost WH, Drużdż A, Pandey S, et al. Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres. Neurol Neurochir Pol. 2021; 55(2): 174–178.
  16. Smit M, Kamphuis ASJ, Bartels AL, et al. Fatigue, Sleep Disturbances, and Their Influence on Quality of Life in Cervical Dystonia Patients. Mov Disord Clin Pract. 2017; 4(4): 517–523.
  17. Camargo CH, Cattai L, Teive HA. Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment. Toxins (Basel). 2015; 7(6): 2321–2335.
  18. Domitrz I, Sławek J, Słowik A, et al. Onabotulinumtoxin A (ONA-BoNT/A) in the treatment of chronic migraine. Neurol Neurochir Pol. 2022; 56(1): 39–47.
  19. Kaya E, Zinnuroglu M, Tugcu I. Kinesio taping compared to physical therapy modalities for the treatment of shoulder impingement syndrome. Clin Rheumatol. 2011; 30(2): 201–207.
  20. Marciniec M, Szczepańska-Szerej A, Kulczyński M, et al. Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: what is currently known? Rev Neurosci. 2019; 30(7): 771–779.
  21. Siongco PR, Rosales RL, Moore AP, et al. Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. J Neural Transm (Vienna). 2020; 127(6): 935–951.
  22. Filippi GM, Errico P, Santarelli R, et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993; 113(3): 400–404.
  23. Park J, Park HJ. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins (Basel). 2017; 9(9).
  24. Kim DW, Lee SK, Ahnn J. Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception. Toxins. 2015; 7(7): 2435–2453.
  25. Relja M, Miletić V. When movement disorders hurt: Addressing pain in hyperkinetic disorders. Parkinsonism Relat Disord. 2017; 44: 110–113.
  26. Kaya E, Zinnuroglu M, Tugcu I. Kinesio taping compared to physical therapy modalities for the treatment of shoulder impingement syndrome. Clin Rheumatol. 2011; 30(2): 201–207.
  27. González-Iglesias J, Fernández-de-Las-Peñas C, Cleland JA, et al. Short-term effects of cervical kinesio taping on pain and cervical range of motion in patients with acute whiplash injury: a randomized clinical trial. J Orthop Sports Phys Ther. 2009; 39(7): 515–521.
  28. Karadag-Saygi E, Cubukcu-Aydoseli K, Kablan N, et al. The role of kinesiotaping combined with botulinum toxin to reduce plantar flexors spasticity after stroke. Top Stroke Rehabil. 2010; 17(4): 318–322.
  29. Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007; 22(2): 95–100.
  30. Dressler D, Tacik P, Saberi FA. Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm (Vienna). 2015; 122(2): 297–300.
  31. Eichenseer SR, Stebbins GT, Comella CL. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014; 20(4): 405–408.
  32. Car H, Bogucki A, Bonikowski M, et al. Botulinum toxin type-A preparations are not the same medications - basic science (Part 1). Neurol Neurochir Pol. 2021; 55(2): 133–140.
  33. Sławek J, Bogucki A, Bonikowski M, et al. Botulinum toxin type-A preparations are not the same medications - clinical studies (Part 2). Neurol Neurochir Pol. 2021; 55(2): 141–157.



Neurologia i Neurochirurgia Polska